Determination of biomarkers for intermediate end points in chemoprevention trials

J. S. Lee, S. M. Lippman, W. K. Hong, J. Y. Ro, S. Y. Kim, R. Lotan, W. N. Hittelman

Research output: Contribution to journalArticle

55 Scopus citations

Abstract

Renewed interest is being directed toward chemoprevention as a means of reducing cancer mortality. To overcome the inherent problems associated with using cancer development as a study end point, there has recently been a great surge of interest in defining the biomarkers associated with specific stages of the carcinogenic process as intermediate end points. We have detailed the evidence supporting the concept of field eancerization, a concept of general importance that is probably applicable to carcinogenesis and chemoprevention at many organ sites in humans, and presented results of tests of the potentially useful biomarkers proliferating cell nuclear antigen and blood group antigen. Because microassay techniques are more readily applicable to small biopsy samples, further expansion of these studies and exploration of panels of additional biomarkers are expected to generate exciting results in the field of chemoprevention.

Original languageEnglish (US)
Pages (from-to)2707s-2710s
JournalCancer research
Volume52
Issue number9 SUPPL.
StatePublished - 1992

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Determination of biomarkers for intermediate end points in chemoprevention trials'. Together they form a unique fingerprint.

Cite this